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M A J O R A R T I C L E
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Background. We assessed immune activation after antiretroviral therapy (ART) initiation to understand clinical failure in di-
verse settings.
Methods. We performed a case-control study in ACTG Prospective Evaluation of Antiretrovirals in Resource-Limited Settings
(PEARLS). Cases were deﬁned as incident World Health Organization Stage 3 or 4 human immunodeﬁciency virus (HIV) disease or
death, analyzed from ART weeks 24 (ART24) to 96. Controls were randomly selected. Interleukin (IL)-6, interferon (IFN)-γ-inducible
protein-10, IL-18, tumor necrosis factor-α, IFN-γ, and soluble CD14 (sCD14) were measured pre-ART and at ART24 in plasma. Con-
tinued elevation was deﬁned by thresholds set by highest pre-ART quartiles (>Q3). Incident risk ratios (IRRs) for clinical progression
were estimated by Poisson regression, adjusting for age, sex, treatment, country, time-updated CD4+ T-cell count, HIV ribonucleic acid
(RNA), and prevalent tuberculosis.
Results. Among 99 cases and 234 controls, median baseline CD4+ T-cell count was 181 cells/µL, and HIV RNAwas 5.05 log10 cp/
mL. Clinical failure was independently associated with continued elevations of IL-18 (IRR, 3.03; 95% conﬁdence interval [CI], 1.27–
7.20), sCD14 (IRR, 2.17; 95% CI, 1.02–4.62), and IFN-γ (IRR, 0.08; 95% CI, 0.01–0.61). Among 276 of 333 (83%) whowere virologically
suppressed at ART24, IFN-γ was associated with protection from failure, but the association with sCD14 was attenuated.
Conclusions. Continued IL-18 and sCD14 elevations were associated with clinical ART failure. Interferon-γ levels may reﬂect pre-
served immune function.
Keywords. antiretroviral therapy; HIV; IFN-γ; inﬂammasome; IL-18; immune activation.
Despite the success of combination antiretroviral therapy
(ART), a subset of human immunodeﬁciency virus (HIV)-
infected patients who initiate ART develop early clinical
progression to acquired immune deﬁciency syndrome (AIDS)
[1–6]. Clinical progression can occur even among patients who
achieve complete viral suppression, termed clinical failure.
Whereas clinical failure during ART has been attributed to
CD4+ T-cell count, continued viremia, and nonadherence [5],
there remains a subset of ART initiators for whom failure is
unexplained. In addition to providing insight into mechanisms
of clinical failure, biomarkers of failure may allow development
of screening algorithms to identify HIV-infected ART initiators
who are at higher risk for failure. A screening strategy in ART ini-
tiators would be of particular interest in resource-limited settings
for those lacking traditional risk factors for clinical failure.
HIV progression has been linked to prolonged immune acti-
vation, a multipronged phenotype that involves dysregulation of
the immune system [7, 8]. Upon ART initiation, immune acti-
vation is only partially attenuated, and not equally among all
people [9–12]. We hypothesized that a subset of immune acti-
vation biomarkers measurable in ART initiators would not be
suppressed by ART and might predict clinical failure. The Pro-
spective Evaluation of Antiretrovirals in Resource-Limited Set-
tings (PEARLS) study was an AIDS Clinical Trials Group
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(ACTG)-sponsored randomized controlled clinical trial of ART
among HIV-infected persons in 9 countries in which enrolled
participants were observed for 96 weeks or more and HIV-related
outcomes were rigorously characterized [6]. We examined
whether continued elevation of immune activation biomarkers
after ART initiation was associated with clinical failure among
PEARLS participants.
METHODS
The ACTG PEARLS study (A5175; ClinicaTrials.gov
NCT00084136) was a Phase IV randomized controlled trial of
3 ART regimens in 1571 treatment naive adults, performed in
Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, the
United States, and Zimbabwe [6]. Eligible participants had
CD4+ T-cell counts <300 cells/mm3 and no recent acute illness
(ie, pneumonia, gastroenteritis, or pelvic inﬂammatory disease)
or opportunistic infections. Participants were randomized to re-
ceive lamivudine/zidovudine/efavirenz (3TC/ZDV/EFV), dida-
nosine/emtricitabine/atazanavir (ddI/FTC/ATV), or tenofovir/
emtricitabine/efavirenz (TDF/FTC/EFV). Informed consent,
including permission to use biological materials, was obtained
from all participants, and the human experimentation guide-
lines of the US Department of Health and Human Services
and local site institutional review boards and ethics committees
were followed. We designed a nested case-control study where
cases (n = 236) were deﬁned by incident World Health Organi-
zation Stage 3 or 4 event or death: among cases, only those who
developed the primary outcome after 24 weeks of ART (ART24)
and prior to 96 weeks after ART initiation (ART96) were re-
tained for analysis (see Supplementary Digital Content 1 for
sample selection). In secondary analyses, only cases and con-
trols who achieved virological suppression by ART24 were ex-
amined for continued elevation of biomarkers that predicted
clinical failure. A randomly selected subcohort (n = 270, or 30
participants from each of 9 sites) from the full cohort of 1571
was used to estimate the prevalence of continued immune
activation.
Biomarkers of immune activation (interleukin [IL]-6, inter-
feron [IFN]-γ-inducible protein-10 [IP-10], IL-18, soluble
CD14 [sCD14], tumor necrosis factor [TNF]-α, and IFN-γ)
were measured in plasma samples obtained at pre-ART and
ART24. Each assay was performed in a single laboratory testing
site to avoid laboratory-to-laboratory variation. Enzyme-linked
immunosorbent assay (ELISA) kits were used for measurement
of sCD14 (R&D Systems, Inc., Minneapolis, MN) and IL-18
(Platinum ELISA; eBiosciences, San Diego, CA). Interferon-γ-
inducible protein-10 (CXCL10) was measured using com-
mercially available test kits (electrochemiluminescent bridging
immune-assay; Meso-Scale Discovery, Gaithersburg, MD).
Soluble IL-6, TNF-α, and IFN-γweremeasured using the Luminex
multiplex cytokine platform (R&D Systems, Inc., Minneapolis,
MN).
Statistical Analyses
All biomarkers were parameterized in quartiles to accommodate
right- or left-censored data. Continued elevation of immune
activation biomarkers was deﬁned individually for each bio-
marker: (1) the threshold for elevated levels of a given bio-
marker was set at >Q3 pre-ART; (2) if at ART24 an elevated
biomarker did not decrease to below the threshold set pre-
ART, it was considered to have continued elevation in that par-
ticipant. Univariable analysis was done to assess the effect of
baseline covariates on continued immune activation. Variables
that were signiﬁcant in the univariable analysis, and ones that
were biologically plausible, were included in the multivariate
modeling. Poisson regression analysis was used to estimate in-
cidence risk ratios (IRRs) for persistent immune activation, ad-
justing for baseline age, sex, treatment, country, CD4+ T-cell
count pre-ART and at ART24, log10 HIV ribonucleic acid
(RNA) level at baseline, viral suppression at ART24 (HIV
RNA level <400 cp/mL), and prevalent tuberculosis (TB).
Time-updated CD4+ T-cell counts were included in models to
account for immune reconstitution with ART.
RESULTS
Baseline Characteristics
Of 470 evaluable participants in the PEARLS study, 137 persons
were excluded from the primary analysis at ART24 after already
achieving the primary outcome or after having been lost to fol-
low-up. The case-control study contained 333 persons at base-
line (see Supplementary Digital Content 1 for sample selection):
99 (29.7%) cases developed clinical failure, and 234 (70.3%)
were controls. The median age overall was 34 years (interquar-
tile range [IQR], 29–40), 160 (48%) were female, and 172 (52%)
were black. The percentage of participants from each country
ranged from 9% to 16% (Table 1). The median baseline CD4+
T-cell count was 180 cells/µL (IQR, 94–229) and HIV RNA
level was 5.05 log10 cp/mL (IQR, 4.54–5.45). Tuberculosis was
prevalent in 20% of the cohort at baseline. Cases and controls
did not differ by baseline CD4+ T-cell count, HIV-1 RNA level,
or ART regimen but did differ by country of origin (P < .001),
and a higher proportion of cases had TB at baseline (30%) than
controls (16%; P = .004). Major outcomes that occurred beyond
ART24 included opportunistic infections (8.0%), newly diag-
nosed TB (25.6%), >10% weight loss (10.0%), and cytopenias
(14.0%) (see Supplementary Digital Content 2, for a delineation
of major outcomes).
Prevalence of Continued Biomarker Elevation After Antiretroviral
Therapy Initiation
Biomarkers of immune activation were measured in partici-
pants’ plasma pre-ART and at ART24. Using the standardized
deﬁnition (levels >Q3 pre-ART), cutoffs for continued elevation
of immune activation biomarkers were set for IL-6 (>48.3 pg/
mL), IP-10 (>2856 pg/mL), IL-18 (>774 pg/mL), sCD14
(>6.4 log10 pg/mL), TNF-α (>28.4 pg/mL), and IFN-γ (>48
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pg/mL). The prevalence of continued elevation of each bio-
marker was estimated in the random subcohort using these cut-
offs (Table 2). Reductions of elevated biomarker levels after
ART initiation did not occur uniformly in all participants: for
IP-10 and TNF-α, only 2% (95% conﬁdence interval [CI],
.3%–4%) and 3% (95% CI, 1%–6%) of participants, respectively,
had continued elevations. Similarly, continued elevation of IL-
18 was found in 5% (95% CI, 3%–9%) of participants. In con-
trast, continued elevations of IL-6 (prevalence 15%; 95% CI,
19%–21%), sCD14 (prevalence 10%; 95% CI, 6%–15%), and
IFN-γ (prevalence 18%; 95% CI, 13%–23%) were more com-
mon after ART initiation.
Correlates of Continued Biomarker Elevation
Several baseline characteristics were associated with persistent
biomarker elevation (Supplementary Digital Content 3). This
included country (P < .05) and age, where older participants
were more likely to have continued elevation of IL-6 (P = .01)
and IP-10 (P = .03), with trends toward signiﬁcance for TNF-
α (P = .09) and IFN-γ (P = .06). Higher baseline HIV RNA
level was also associated with continued elevation of sCD14
(P = .002) and IFN-γ (P = .02), and it was marginally associated
with continued IP-10 (P = .07) elevation. Continued elevation
of sCD14 was associated with the ART treatment arm, with
the highest prevalence occurring among persons who received
3TC/ZDV/EFV and the lowest prevalence among persons who
received TDF/FTC/EFV (P = .001). In addition, the prevalence
of continued elevation of TNF-α was marginally higher among
persons who did not achieve virologic suppression at ART24
(P = .09), whereas the prevalence of continued elevation of
IFN-γ was marginally lower among persons who did not
achieve virologic suppression at ART24 (P = .06). Baseline TB
was not associated with continued biomarker elevation.
Continued Biomarker Elevation and Clinical Failure
Poisson regression models were developed to test whether con-
tinued elevation of each biomarker deleteriously contributed
to clinical failure. In univariate analyses, continued elevation
Table 1. Baseline Characteristics of Study Population
Baseline Characteristics Overall (n = 333) Cases (n = 99) Controls (n = 234) P Value
Female, n (%) 160 (48%) 45 (45%) 115 (49%) .55
Age, median (IQR) 34 (29–40) 34 (28–38) 35 (29–41) .20
Race .013
White 85 (26%) 36 (36%) 49 (21%)
Black or African Americans 172 (52%) 49 (49%) 123 (53%)
Asian 36 (11%) 8 (8%) 28 (12%)
Other 38 (11%) 6 (6%) 32 (14%)
Country <.001
Brazil 36 (11%) 7 (7%) 29 (12%)
Haiti 30 (9%) 5 (5%) 25 (11%)
India 53 (16%) 33 (33%) 20 (9%)
Malawi 44 (13%) 20 (20%) 24 (10%)
Peru 32 (10%) 4 (4%) 28 (12%)
South Africa 38 (11%) 13 (13%) 25 (11%)
Thailand 31 (9%) 3 (3%) 28 (12%)
United States 37 (11%) 8 (8%) 29 (12%)
Zimbabwe 32 (10%) 6 (6%) 26 (11%)
CD4+ T cells/μL, median (IQR) 180 (94–229) 182 (108–216) 180 (90–233) .42
Log10 HIV RNA cp/mL, median (IQR) 5.05 (4.54–5.45) 5.05 (4.53–5.43) 5.02 (4.55–5.47) .91
TB, n (%) 67 (20%) 30 (30%) 37 (16%) .004
HBsAg, n (%) 15 (5%) 2 (2%) 13 (6%) .25
HIV RNA < 400 cp/mL (Week 24), n (%) 276 (87%) 74 (77%) 202 (91%) .002
Abbreviations: HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid; TB, tuberculosis.
Table 2. Prevalence of Continued Immune Activation After 24 Weeks of
ART (ART24)a,b
Marker N IQR (pg/mL) Prevalence 95% CI
IL-6 200 9.1–48.3 15% (19%–21%)
IP-10 200 601–2856 2% (.3%–4%)
IL-18 193 163–774 5% (3%–9%)
sCD14 199 5.7–6.4c 10% (6%–15%)
TNF-α 200 13.7–28.4 3% (1%–6%)
IFN-γ 200 5.6–48 18% (13%–23%)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IFN, interferon; IL,
interleukin; IP, IFN-γ-inducible protein; sCD14, soluble CD14; TNF, tumor necrosis factor.
a The prevalence of continued immune activation was estimated at ART24 in the random
subcohort.
b Continued immune activation was defined for each biomarker separately. Based on the
distribution of each biomarker at baseline, continued elevation was defined when
biomarker levels exceeded the third quartile cutoff pre-ART.
c Log10 pg/mL values of sCD14 are shown.
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of IL-18, sCD14, and IFN-γ each separately predicted clinical
failure (Table 3). Continued elevation of IL-6, IP-10, and
TNF-α appeared to have no association with clinical failure.
A multivariable analysis was performed, adjusting for age, sex,
country, random treatment assignment group, baseline BMI,
time-updated CD4+ T-cell count (at ART24), log10 HIV RNA
level, and prevalent TB. Continued IL-18 elevation remained
strongly associated with clinical failure (IRR, 3.03; 95% CI,
1.27–7.20; P = .012), as did sCD14 (IRR, 2.17; 95% CI, 1.02–
4.62; P = .045). In contrast, continued elevation of IFN-γ was as-
sociated with a lower likelihood of developing clinical failure
(IRR, 0.08; 95% CI, .01–.61; P = .02).
Not all ART initiators achieved virologic suppression at
ART24, which could contribute to and confound an analysis
of immune activation. Therefore, multivariate models were de-
veloped that adjusted for virologic suppression at ART24 in ad-
dition to the previous covariates. The new models continued to
show associations between clinical progression and continued
elevation of IL-18 (IRR, 2.99; 95% CI, 1.22–7.31; P = .02) and
sCD14 (IRR 2.08; 95% CI, .96–4.49; P = .06). Likewise, the
association between continued IFN-γ elevation and a decreased
likelihood of developing clinical failure was maintained after
adjustment for virologic suppression (IRR, 0.08; 95% CI,
.01–.62; P = .02). As an added measure to avoid potential con-
founding from incomplete virologic suppression, a secondary
analysis was performed that was restricted to only cases and
controls who were virologically suppressed at ART24 (n = 276;
cases = 74, controls = 202), although this decreased the power to
observe associations (Table 4). Continued elevation of IL-18
was associated with a 2.84 IRR (95% CI, .97–8.29; P = .06) of
clinical failure, whereas continued elevation of IFN-γ was asso-
ciated with a 0.08 IRR (95% CI, .01–.63; P = .02) of clinical fail-
ure. More importantly, IL-18 and IFN-γ levels were not closely
correlated with each other at any time point (data not shown).
The association of clinical failure with continued elevation of
sCD14 was attenuated: 2.11 IRR (95% CI, .82–5.43; P = .12).
Kaplan–Meier survival analyses were performed among 333
persons in the primary analysis group with or without continued
elevations of IL-18, sCD14, and IFN-γ (Figure 1). At ART96, per-
sons with continued elevations of IL-18 had signiﬁcantly more
Table 3. Univariable and Multivariable Analysis for Clinical Failure at 96 Weeks (ART96)
Marker >Q3
(ART24) Overall Case Control
Univariable Analysis
Multivariable Analysis
Model 1a
Multivariable Analysis
Model 2b
IRR (95% CI) P Value IRR (95% CI) P Value IRR (95% CI) P Value
IL-6 34 of 249 (14%) 6 of 57 (11%) 28 of 192 (15%) 0.65 (.28–1.52) .33 0.62 (.25–1.52) .29 0.62 (.25–1.54) .30
IP-10 5 of 249 (2%) 2 of 57 (4%) 3 of 192 (2%) 2.39 (.58–9.79) .23 2.27 (.45–11.33) .32 2.35 (.48–11.78) .30
IL-18 16 of 242 (7%) 8 of 56 (14%) 8 of 186 (4%) 2.86 (1.35–6.04) .006 3.03 (1.27–7.20) .012 2.99 (1.22–7.31) .02
sCD14 33 of 246 (13%) 13 of 54 (24%) 20 of 192 (10%) 2.42 (1.30–4.51) .006 2.17 (1.02–4.62) .045 2.08 (.96–4.49) .06
TNF-α 9 of 249 (4%) 3 of 57 (5%) 6 of 192 (3%) 1.23 (.38–3.93) .73 1.05 (.29–3.73) .94 0.99 (.28–3.59) >.95
IFN-γ 36 of 249 (14%) 1 of 57 (2%) 35 of 192 (18%) 0.10 (.01–.74) .02 0.08 (.01–.61) .02 0.08 (.01–.62) .02
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HIV, human immunodeficiency virus; IFN, interferon; IL, interleukin; IP, IFN-γ-inducible protein;
IRR, incidence rate ratio; sCD14, soluble CD14; TNF, tumor necrosis factor.
a Model 1 was adjusted for age, sex, country, random treatment assignment, baseline BMI, time-updated CD4+ T-cell count at ART24, baseline log10 HIV RNA level, and baseline TB.
b Model 2 was adjusted for age, sex, country, random treatment assignment, baseline BMI, time-updated CD4+ T-cell count at ART24, baseline log10 HIV RNA level, baseline TB, and viral
suppression at ART24 (HIV RNA <400 cp/mL).
Table 4. Univariable and Multivariate Models of Clinical Failure at ART96 Among Persons Who Were Virologically Suppresseda
Marker >Q3
(ART24) Overall Case Control
Univariable Analysis Multivariable Analysis
IRR (95% CI) P Value IRR (95% CI) P Value
IL-6 30 (14%) 5 (11%) 25 (14%) 0.72 (.28–1.81) .48 0.59 (.22–1.60) .30
IP-10 4 (2%) 2 (6%) 2 (1%) 2.93 (.71–12.1) .14 2.83 (.53–15.1) .22
IL-18 12 (6%) 5 (12%) 7 (4%) 2.68 (1.05–6.82) .04 2.84 (.97–8.29) .06
sCD14 26 (12%) 9 (22%) 17 (10%) 2.51 (1.20–5.26) .02 2.11 (.82–5.43) .12
TNF-α 6 (3%) 1 (3%) 5 (3%) 0.62 (.09–4.51) .64 0.60 (.07–5.05) .64
IFN-γ 35 (16%) 1 (2%) 34 (20%) 0.12 (.02–0.87) .04 0.08 (.01–.63) .02
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; IFN, interferon; IL, interleukin; IP, IFN-γ-inducible protein; IRR, incidence rate ratio; sCD14, soluble CD14; TNF, tumor necrosis
factor.
a The multivariable model was adjusted for age, sex, country, random treatment assignment, baseline BMI, time-updated CD4+ T-cell count at ART24, baseline log10 HIV RNA level, and
baseline TB.
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occurrences of clinical failure compared with persons without
continued IL-18 elevations (P = .004), and there was a similar
trend for sCD14 (P = .006). In parallel, persons with continued
elevations of IFN-γ levels had signiﬁcantly less clinical failure
at ART96 than persons who had lower IFN-γ levels at baseline,
24 weeks, or at both time points (P = .003).
DISCUSSION
In a diverse multicountry cohort of persons predominantly
from low- and middle-income countries, we found that HIV-
infected ART initiators with high levels of IL-18 and sCD14
pre-ART that failed to normalize during ART were more likely
to develop clinical failure than persons who did not have con-
tinued high levels of these biomarkers. Continued IFN-γ elevation
was strongly associated with protection from clinical failure. Re-
peated measurements of IL-18, sCD14, and IFN-γ may be useful
in identifying ART-naive persons for whom ART initiation alone
may not be sufﬁcient to prevent HIV complications.
IL-18 and sCD14 are measures of monocyte activation. IL-18
is released upon stimulation of the inﬂammasome, a multicom-
ponent intracellular protein complex involved in innate immune
signaling [13]. Human immunodeﬁciency virus virions are po-
tent inﬂammasome triggers in circulating monocytes [14]. In-
ﬂammasome activation primes defenses against intracellular
pathogens, and persistently elevated serum IL-18 levels have
been associated with unfavorable outcomes among HIV-infected
[15, 16] and HIV-uninfected persons [17–19]. Whereas in the
present study we did not ascertain non-AIDS outcomes, the
strong association of continued elevation of IL-18 with clinical
failure suggests that ART does not fully turn off inﬂammasome
signaling. Interleukin-18 elevations pre-ART have been associat-
ed with TB immune reconstitution inﬂammatory syndrome [20],
although our ﬁndings were not driven by that outcome. Mono-
cyte activation with sCD14 release has been increasingly recog-
nized as a key component of the immune activation phenotype
that drives AIDS pathogenesis. Indeed, Hasegawa et al [21] found
that monocyte turnover in simian immunodeﬁciency virus
(SIV)-infected macaques was the strongest predictor of mortality
even after considering SIV RNA and CD4+ T-cell depletion.
However, it is still unclear how monocyte activation contributed
to the diverse outcomes in the present study and what triggers
continued monocyte activation in the absence of detectable plas-
ma viremia, although microbial translocation and type 1 IFN sig-
naling have both been proposed.
Continued IFN-γ elevation was protective against clinical
failure despite its association with pre-ART HIV RNA. Al-
though IFN-γ is a critical component of pathogen-speciﬁc im-
munity, we measured bulk levels in circulation and not in
association with any particular pathogen. The source of plasma
IFN-γ was unclear; CD8+ T cells, natural killer (NK) cells, and
to some degree CD4+ T cells are robust producers of IFN-γ. To
explain why IFN-γ may have been beneﬁcial, we speculate that
IFN-γ levels reﬂect retained functionality of CD8+ T cells that
are speciﬁc for opportunistic infections despite HIV-associated
immunosuppression before ART initiation. Natural killer cells
have been reported to be pathologically activated in HIV, a
Figure 1. Kaplan–Meier survival in persons who have persistent immune activa-
tion. Kaplan-Meier curves are shown for (A). Interleukin (IL)-18 (P = .004). (B) Soluble
CD14 (sCD14) (P = .006), and (C) interferon (IFN)-γ (P = .003), beginning after ART24
to reflect censoring of individuals who achieved outcomes before 24 weeks.
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phenotype that is only partially reversed by ART [22, 23].
Whereas NK cell activation has been assumed to have negative
consequences in HIV, a more complex relationship between NK
cell activation and HIV progression is conceivable, especially
during ART. It is compelling to consider that IFN-γ itself is pro-
tective in ART initiators. In the case of TB, one of the leading
diagnoses that contributed to clinical failure, genetic deﬁcien-
cies of IFN-γ or dysfunctional IFN-γ signaling can lead to severe
disease [24]. Similar genetic differences in IFN-γ signaling may
have contributed to our results. However, exogenous IFN-γ ad-
ministration to HIV-infected persons has yielded mixed results
[25]. In addition, IFN-γ levels in our study were far in excess
than what has been reported among healthy controls [26, 27].
Therefore, the implications of continued IFN-γ elevation will
need to be explored further in prospective studies.
Previous studies during ART have largely found that immune
activation decreases with virologic control, although a minority
of treated patients have normalized immune activation markers.
As an example, CD4+ and CD8+ T-cell activation appeared to re-
duce with ART by 0.06% and 0.1%, respectively [28]. Likewise,
sCD14, which when measured before ART initiation has been
linked with mortality, did not decline to levels found in HIV-
uninfected persons during ART [8, 29]. The microbial trans-
location marker lipopolysaccharide shared the same pattern of
decrease without normalization [29]. IL-6, one of the strongest
predictors of mortality and AIDS in untreated HIV-infected
patients and in patients initiating ART, did not change apprecia-
bly during ART [30–32], a ﬁnding underscored by us here and
previously [33]. Although several immune activation markers
have been characterized pre-ART, few studies have examined
how continued immune activation during ART affects treatment
outcome, particularly in resource-constrained countries, from
where the majority of study population was recruited. Tien et al
[34] reported that persistently elevated ﬁbrinogen and C-
reactive protein in ART-treated HIV-infected persons had an in-
creased risk of mortality. To our knowledge, ours is the ﬁrst
study to identify IL-18 and IFN-γ as immune activation markers
that could potentially be followed during ART to predict early
outcomes.
There are some limitations to our study. A universal deﬁni-
tion of persistent immune activation that encompasses all
markers does not exist; participants for whom continued eleva-
tion of one marker was found did not necessarily have contin-
ued elevation of all markers, reﬂecting the complexity of stimuli
that result in immune activation. By deﬁning continued im-
mune activation for each biomarker separately, we answered
the question that is most relevant to a treating physician; name-
ly, whether measurement of a given marker will indicate which
patients will require added vigilance after ART initiation. A re-
lated point is that we used empiric cutoffs to determine eleva-
tions of each biomarker because there are no known cutoffs
deﬁning abnormal elevations for the biomarkers that we used.
By using the same empiric deﬁnition for continued elevations to
each biomarker, we have normalized the analysis of each bio-
marker to allow comparisons between them, although it is pos-
sible that we consequently reduced our power to identify other
associations of importance. A second challenge was in inter-
preting biomarker levels across multiple countries, where expo-
sures to prevalent infections are likely to be different. By
adjusting for country, we have partially accounted for different
exposures. It will be important to conﬁrm our ﬁndings in sep-
arate cohorts and in separate geographical areas. A third limita-
tion is in interpreting serum IFN-γ levels. If, as we speculate,
serum IFN-γ is produced by CD8+ T cells, then in future studies
IFN-γ production by pathogen-speciﬁc CD8+ T cells should be
quantiﬁed to test whether elevated IFN-γ levels are the result of
retained or restored pathogen-speciﬁc immunity. Future studies
should also include examination of cellular immune activation
markers longitudinally during ART, although these were not
available in the present study. A fourth limitation is that
IFN-γ, IL-18, and IP-10 are typically linked mechanistically:
IP-10 is typically induced by IFN-γ stimulation, whereas
IL-18 induces IFN-γ in T-cell subsets. Intriguingly, we found
reciprocal associations of continued IL-18 elevation and IFN-
γ elevation with clinical failure. Further research is required to
understand the complexity of these signaling networks.
CONCLUSIONS
In summary, we found that among HIV-infected ART initiators,
elevation of IL-18 and sCD14 pre-ART and at ART24 predicted
clinical failure, whereas IFN-γ elevation appeared to be favorable.
There is clinical value in identifying markers that predict failure
after starting ART. Point-of-care tests are being developed for
biomarkers that can be readily deployed in resource-limited set-
tings. Therefore, because the present dogma to “test and treat”
may be insufﬁcient for some people with HIV, an expanded
algorithm of “test, treat, and stratify” into risk groups by measur-
ing IL-18, sCD14, and IFN-γ may be a more comprehensive ap-
proach to avoid the pitfalls of delayed clinical progression that
can occur even among persons who are virologically suppressed.
In addition, dampening of residual immune activation, such as
has been proposed pharmacologically for the inﬂammasome
[35, 36], may reduce the likelihood of clinical progression.
Supplementary Data
Supplementary material is available online atOpen Forum Infectious Diseases
online (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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